SandesaraPBO’NealWTKelliHM, et al. The prognostic significance of diabetes and microvascular complications in patients with heart failure with preserved ejection fraction. Diabetes Care. 2018;41(1):150-155.
2.
Dei CasAFonarowGCGheorghiadeMButlerJ.Concomitant diabetes mellitus and heart failure. Curr Probl Cardiol. 2015;40(1):7-43.
3.
FromAMLeibsonCLBursiF, et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med. 2006;119(7):591-599.
4.
NicholsGAGullionCMKoroCEEphrossSABrownJB.The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004;27(8):1879-1884.
5.
9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S98-S110.
6.
VermaSMcMurrayJJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108-2117.
7.
ZinmanBWannerCLachinJM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
8.
NealBPerkovicVMahaffeyKW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657.
9.
WiviottSDRazIBonacaMP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347-357.
10.
ZelnikerTAWiviottSDRazI, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet (London, England). 2019;393(10166):31-39.
11.
McMurrayJJVSolomonSDInzucchiSE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303
12.
McMurrayJJVPackerMDesaiAS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004.
13.
PackerMAnkerSDButlerJ, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424.
14.
ZannadFFerreiraJPPocockSJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet (London, England). 2020;396(10254):819-829.
15.
DasSREverettBMBirtcherKK, et al. 2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the american college of cardiology solution set oversight committee. J Am Coll Cardiol. 2020;76(9):1117-1145.
16.
ShahADLangenbergCRapsomanikiE, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 19 million people. Lancet Diabetes Endocrinol. 2015;3(2):105-113. doi:10.1016/S2213-8587(14)70219-0
17.
CavenderMAStegPGSmithSCJ, et al. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) registry. Circulation. 2015;132(10):923-931.
18.
AstraZeneca. Dapagliflozin evaluation to improve the lives of patients with preserved ejection fraction heart failure (DELIVER). Accessed January 20, 2021. https://clinicaltrials.gov/ct2/show/NCT03619213
19.
Boehringer Ingelheim. Empagliflozin outcome trial in patients with chronic heart failure with preserved ejection fraction (EMPEROR-Preserved). Accessed January 20, 2021. https://clinicaltrials.gov/ct2/show/NCT03057951
